Home▸Anti-Amyloid Monoclonal Antibody Therapy▸Lecanemab Amyloid Plaque Clearance Simulator

🧠 Lecanemab Amyloid Plaque Clearance Simulator

This simulation models the process of amyloid plaque clearance using lecanemab (Leqembi), a drug designed to reduce the presence of amyloid-beta plaques in the brain, which are associated with Alzheimer's disease.

Anti-Amyloid Monoclonal Antibody Therapy2DModerate60 FPS

Lecanemab Seeks Out Amyloid-Beta Protofibrils and Plaques

A short placeholder on antibody targeting of amyloid.

Aβ protofibril: Target (Illustrative binding target)
Humanized IgG1: Antibody type (Illustrative isotype note)
IV infusion: Route (Illustrative dosing note)
Biweekly: Frequency (Illustrative schedule note)

Antibody recognition of amyloid species

Placeholder: antibody scans and recognizes amyloid targets.

Antibody Coating Marks Plaques for Immune Recognition

A short placeholder on plaque opsonization dynamics.

Surface coat: Opsonization (Illustrative coating stat)
FcγR binding: Fc engagement (Illustrative receptor note)
Dense: Coverage (Illustrative density note)
Clearance flag: Signal (Illustrative signal note)

Opsonization marks plaques for clearance

Placeholder: bound antibodies flag plaques for microglia.

Microglia Engulf Antibody-Tagged Amyloid Deposits

A short placeholder on microglial phagocytosis.

Phagocytosis: Mechanism (Illustrative clearance mechanism)
Microglia: Cell type (Illustrative effector cell)
Fc receptor: Trigger (Illustrative trigger note)
Plaque shrinkage: Outcome (Illustrative outcome note)

Microglial engulfment of opsonized plaques

Placeholder: microglia consume tagged plaques over time.

Cumulative Plaque Burden Falls Across the Infusion Course

A short placeholder on burden reduction over months.

0–18 months: Timeline (Illustrative treatment window)
Centiloid: PET metric (Illustrative imaging metric)
Declining: Trend (Illustrative burden trend)
Serial PET: Monitoring (Illustrative monitoring note)

Burden decline over the treatment course

Placeholder: PET burden trends down with more infusions.

Relating Amyloid Clearance to Clinical Outcome Trends

A short placeholder on clearance-outcome correlation.

CDR-SB: Endpoint (Illustrative outcome measure)
Modest: Correlation (Illustrative correlation note)
Monitored: ARIA risk (Illustrative safety note)
Slowed decline: Benefit (Illustrative benefit note)

Clearance versus cognitive outcome trend

Placeholder: greater clearance loosely tracks slower decline.

Placeholder highlight: illustrative only, not clinical guidance.

⚙ Under the hood

CanvasBiomedicine

2D · HTML5 Canvas 2D · 60 FPS target · runs fully client-side, no install